SKS. Konstantinov

S. Konstantinov

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


S. Konstantinov has a total of 4 co-authors. Here are the top co-authors by number of shared publications:

  • A. Kostovski

    Lab. for Experimental Chemotherapy, Dept. of Pharmacology and Toxicology, Faculty of Pharmacy at the Medical University of Sofia, 2 Dunav St., 1000 Sofia, Bulgaria

    1 shared publication
  • M. Berger

    Unit of Toxicology and Chemotherapy, German Cancer Research Center, Im Neuenheimer Feld 280, 69120 Heidelberg, Germany

    1 shared publication
  • M. Genova

    National Centre for Clinical and Transfusion Hematology, Lab. for Flow Cytometry, 6 Plovdivsko pole, 1156 Sofia, Bulgaria

    1 shared publication
  • M. Topashka-Ancheva

    Inst. of Zoology, Bulgarian Academy of Sciences, 1 Tsar Osvoboditel Blvd., 1000 Sofia, Bulgaria

    1 shared publication

Latest Publications

  • Cytotoxic efficacy of bendamustine in human leukemia and breast cancer cell lines

    by S. Konstantinov, A. Kostovski, M. Topashka-Ancheva, M. Genova, M. Berger

    Purpose: The purpose of this study was to characterise bendamustine's cytotoxic and apoptotic activity in a panel of leukemia and breast cancer cell lines in comparison to its clastogenicity in murine bone marrow. Methods: The cytotoxic effect of bendamustine was measured by the 3-(4,5-dimethylthiazol-2-yl)-2,5 diphenyltetrazolium bromide (MTT)-dye reduction assay. Induction of apoptosis was evidenced by DNA gel electrophoresis, nuclear staining, Western blot poly-(adenosine diphosphate-ribose) polymerase (PARP) cleavage, and flow cytometry. As a measure of hematological toxicity, the formation of chromosomal aberrations was investigated in bone marrow cells isolated from mice treated with low non-toxic doses of bendamustine and lomustine. Results: Bendamustine was preferably active against leukemic cells of lymphoid origin and was found to induce apoptosis in SKW-3 and BV-173 cells as shown by oligonucleosomal DNA and nuclear fragmentation, PARP cleavage, and formation of a sub-G1 fraction. Myeloid and breast carcinoma cell lines were resistant towards bendamustine with the exception of HL-60 cells which exhibit an intermediate sensitivity. Bendamustine was found to have a very low clastogenic effect as compared with equimolar doses of lomustine. Conclusion: Taken together, the mode of action of bendamustine includes induction of apoptosis. The specific spectrum of activity and the unexpectedly low clastogenicity support the hypothesis that bendamustine in not a typical alkylating agent but exerts an additional mode of action, possibly as a purine antimetabolite.